AQUEOUS COMPOSITION CONTAINING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDINE-1-YL]CARBONYL} PHENYL)-3-[4-(4,6- DIMORPHOLINE-4-YL-1,3,5-TRIAZINE-2-YL)PHENYL]UREA Russian patent published in 2022 - IPC A61K31/5377 A61K9/08 A61K9/19 A61K47/02 A61K47/12 A61K47/40 A61P35/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine, in particular, to oncology, and is intended for treating cancer. The pharmaceutical aqueous composition contains a compound of 1-(4-{[4-(dimethylamino)piperidine-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholine-4-yl-1,3,5-triazine-2-yl)phenyl]urea, or a pharmacologically acceptable salt thereof with an organic or inorganic acid, a pharmacologically acceptable organic or inorganic acid, pharmacologically acceptable beta- or gamma-cyclodextrins and water, and is in the form of a transparent solution. The group of inventions also relates to a lyophilised composition of the compound; to a pharmaceutical composition in the form of an aqueous solution, containing the lyophilised composition; and to an application of the composition for treating cancer.

EFFECT: implementation of the invention allows for production of a chemically and physically stable pharmaceutical composition of 1-(4-{[4-(dimethylamino)piperidine-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholine-4-yl-1,3,5-triazine-2-yl)phenyl]urea at 25°C with a relative humidity of 60%, and also provides a possibility of facilitating effective intravenous or parenteral administration by creating a more convenient dosage form, namely a vial containing a single dosage of the composition.

34 cl, 1 dwg, 4 tbl, 6 ex